The 90-Day Territory Test: Validating a New Metro Before You Hire Full-Time

Pick a metro. Hire a W2 rep. Wait nine months to find out if you picked right.

That is the playbook most Series A health-techs run when they decide to expand beyond their first geography. It costs around $180K. It eats nine months of runway. It produces one data point.

The 90-day territory test is the alternative. It costs roughly $25K per metro. It takes ninety days. It produces real meeting volume and a defensible read on whether the territory is worth a permanent presence.

I keep getting asked why more companies are not doing it. So this is the math.

The cost comparison, before anything else

The W2 line is the part most VPs of Commercial do not want to look at. You spend more, faster, to get less. The reason is structural. A W2 rep in their first ninety days is learning the product, learning the CRM, building a target list, and starting to dial. They are not yet running plays. A senior contract rep with relationships in the metro skips the first three steps.

That is most of the argument. The rest is detail. (If you want the longer version of why the W2 timeline is what it is, Sara wrote about the six-month failure pattern and it is worth reading before this gets dismissed as too aggressive.)

What the test actually tells you

The thing being tested is not the rep. It is the territory.

A senior contract rep walking into a metro they already cover will tell you four things in ninety days that are very hard to learn from desk research:

The buyer concentration is real, or it is not. Some metros look strong on paper because of population density and provider count, then turn out to have buying authority concentrated in two or three large IDNs that are not yet ready for your product. The contract rep finds that out in three weeks.

The competitive density is workable, or it is not. Sometimes a competitor has already locked up the metro through a regional health system relationship. Desk research will not show you that. A rep with relationships will hear it on the third call.

The regulatory environment supports your motion, or it does not. State licensure rules for telehealth, scope-of-practice variation, payer-specific requirements. These rarely block a sale outright but they slow it down by months in some states.

Your value proposition translates, or it does not. The pitch that worked in Atlanta sometimes lands flat in Phoenix because the local provider economics are different. The rep finds out fast.

If you place a W2 rep into the same metro, you learn these same four things. You just learn them eight months later, having paid roughly seven times more for the privilege.

The activity quota

A 90-day test only works with a defined quota. Without one, you are buying ninety days of unstructured contractor time and getting subjective impressions back. That is worth less than the test costs.

The quota I use:

• Weeks 1 to 2: relationship audit and target list build. No meetings expected.
• Weeks 3 to 13: 8 to 12 qualified meetings per week, depending on density.
• Month 1 deliverable: 25 to 35 completed meetings, ranked by buyer authority.
• Month 2 deliverable: 5 to 10 opportunities with explicit next steps.
• Month 3 deliverable: pipeline review and a written recommendation. Scale, exit, or rotate.

This workload is real. A senior rep at 20 hours per week can hit it if they have territory relationships. A junior rep cannot, which is why this model is not a way to deploy cheap labor. Pay for seniority. The test is only useful if the data coming back is from someone who can actually walk into the buildings.

Scaling the test across multiple metros

Most Series A health-techs are not testing one metro. They are picking the right two or three to commit to out of a candidate set of five or six.

That last row changes the conversation with the board. For roughly the cash cost of one bad W2 hire, you have stress-tested five metros and made an informed decision about which two to commit to. The W2 hires you make after the test are dropped into territories that are already producing pipeline. Ramp is faster because the playbook is no longer hypothetical. (If you want the runway implications of leaving a territory empty in the meantime, the cost of an empty medical sales territory is the cleaner version of that math.)

Where I push back

A few objections come up consistently.

"We do not know senior contract reps at this seniority level exist." Common, especially among VPs at first-time GTM roles in healthcare. The contract market for senior medical sales reps has matured significantly in the last three years. Marketplaces with vetted talent pools now exist. The bigger problem is that the people running these decisions still default to W2 hiring because that is what they know. (The medical sales outsourcing guide covers the talent-pool side of this in more depth.)

"Contract reps will not be committed." They are working to a written quota with weekly reporting. The accountability is tighter than W2, not looser. If the activity is not happening, the contract ends. Try doing that to a W2 rep at month two.

"The board wants headcount additions." The board wants pipeline. Headcount is a proxy. Show up at the next meeting with three contract reps producing 30 qualified meetings per month and the headcount question stops being interesting.

"What about onboarding cost on a contract rep?" Real, but smaller than expected. A senior rep with healthcare experience can absorb a product pitch in a week. Compare to six to eight weeks for a W2 rep coming from outside healthcare.

What this does not replace

The 90-day test is a market entry tool. Not a permanent staffing model.

Three things it does not do.

It does not replace strategic territory selection. You still need desk research, payer mix analysis, and competitive scan before placing reps. The test validates a hypothesis. It does not generate one.

It does not replace permanent territory ownership. If a metro proves out, you eventually need a full-time owner. Contract reps are a market entry vehicle in most B2B health-tech motions, not a destination.

It does not replace brand-building. Direct outreach is what the test produces. Conference presence, content, thought leadership, all of that runs in parallel and on a different timeline.

The test answers one question. Is this territory worth a permanent presence. Fast and cheap, before you commit a quarter of your runway to a permanent hire.

The math is not complicated. The barrier is habit.